Advertisement

Outpatient Parenteral Antimicrobial Therapy in Children

  • Sanjay PatelEmail author
  • Helen Green
Pediatric Infectious Diseases (I Brook, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pediatric Infectious Diseases

Abstract

Purpose of Review

Over recent years, there has been a marked increase in the number of centres delivering paediatric outpatient parenteral antimicrobial therapy (pOPAT). Various factors have fuelled this drive, including the significant economic pressures faced by high-income countries to contain the cost of healthcare, resulting in a significant reduction of in-patient beds over the past 20 years. It is essential that pOPAT services have formal clinical governance structures in place to ensure the safe and effective management of children being ambulated on intravenous antibiotics. They also require oversight of antimicrobial decisions by a medically qualified infection specialist to ensure that the principles of antimicrobial stewardship are adhered to. This review aims to provide an evidence-based framework for delivering pOPAT services.

Recent Findings

There is increasing data supporting the implementation of admission avoidance strategies for children with cellulitis and pyelonephritis. In addition, recent data supports the management of a subset of children with febrile neutropenia within pOPAT services. Above all, there is a clear recognition that embedding antimicrobial stewardship within pOPAT services reduces duration of intravenous antibiotics (IVAbs) and improves patient management.

Summary

pOPAT services are safe, cost-effective and associated with high levels of parent/patient satisfaction. Further research is required to develop risk prediction models for children being considered for pOPAT. Further data about the use of elastomeric devices in children and the acceptability of parental administration of IVAbs are also required.

Keywords

Outpatient parenteral antimicrobial therapy Antimicrobial stewardship Antibiotic stewardship pOPAT Hospital at home Ambulatory antibiotics Children Paediatrics 

Notes

Compliance with Ethical Standards

Conflict of Interest

Sanjay Patel and Helen Green declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Patel S, Abrahamson E, Goldring S, Green H, Wickens H, Laundy M. Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement. J Antimicrob Chemother. 2015;70(2):360–73 An evidence based national guideline covering all the areas involved in setting up and running a pOPAT service. CrossRefPubMedGoogle Scholar
  2. 2.
    Patel S, Burzio V, Green H, Rees S, Tebruegge M, Jones C, et al. The impact of pediatric outpatient parenteral antibiotic therapy implementation at a tertiary children’s hospital in the United Kingdom. Pediatr Infect Dis J. 2018;37(12):e292–e7.CrossRefPubMedGoogle Scholar
  3. 3.
    Hensher M, Edwards N, Stokes R. International trends in the provision and utilisation of hospital care. BMJ. 1999;319(7213):845–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bryant PA, Hopper SM. Alternatives to ward admission from the emergency department. J Paediatr Child Health. 2016;52(2):237–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Minton J, Murray CC, Meads D, Hess S, Vargas-Palacios A, Mitchell E, et al. The community IntraVenous antibiotic study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy. Southampton: Health Services and Delivery Research; 2017.Google Scholar
  6. 6.
    Bradford N, Armfield NR, Young J, Ehmer M, Lawson R, Smith AC. Internet video to support intravenous medication administration in the home: a cost minimisation study. J Telemed Telecare. 2013;19(7):367–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Castor C, Landgren K, Hansson H, Kristensson HI. A possibility for strengthening family life and health: family members’ lived experience when a sick child receives home care in Sweden. Health Soc Care Community. 2018;26(2):224–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Peltola H, Paakkonen M, Kallio P, Kallio MJ. Osteomyelitis-septic arthritis study G. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis. 2009;48(9):1201–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Peltola H, Paakkonen M. Acute osteomyelitis in children. N Engl J Med. 2014;370(4):352–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Keren R, Shah SS, Srivastava R, Rangel S, Bendel-Stenzel M, Harik N, et al. Comparative effectiveness of intravenous vs oral antibiotics for postdischarge treatment of acute osteomyelitis in children. JAMA Pediatr. 2015;169(2):120–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Bocquet N, Sergent Alaoui A, Jais JP, Gajdos V, Guigonis V, Lacour B, et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics. 2012;129(2):e269–75.CrossRefPubMedGoogle Scholar
  12. 12.
    Arnold MR, Wormer BA, Kao AM, Klima DA, Colavita PD, Cosper GH, et al. Home intravenous versus oral antibiotics following appendectomy for perforated appendicitis in children: a randomized controlled trial. Pediatr Surg Int. 2018;34:1257–68.CrossRefPubMedGoogle Scholar
  13. 13.
    Stockmann C, Ampofo K, Pavia AT, Byington CL, Sheng X, Greene TH, et al. Comparative effectiveness of Oral versus outpatient parenteral antibiotic therapy for empyema. Hosp Pediatr. 2015;5(12):605–12.CrossRefPubMedGoogle Scholar
  14. 14.
    • Hersh AL, Olson J, Stockmann C, Thorell EA, Knackstedt ED, Esquibel L, et al. Impact of antimicrobial stewardship for pediatric outpatient parenteral antibiotic therapy. J Pediatric Infect Dis Soc. 2018;7(2):e34–e6 Clear demonstration of the importunate of embedding antimicrobial stewardship principles within an pOPAT service; this study describes the impact of expert review on antibiotic use. CrossRefPubMedGoogle Scholar
  15. 15.
    Knackstedt ED, Stockmann C, Davis CR, Thorell EA, Pavia AT, Hersh AL. Outpatient parenteral antimicrobial therapy in pediatrics: an opportunity to expand antimicrobial stewardship. Infect Control Hosp Epidemiol. 2015;36(2):222–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Xu M, Doan Q. Outpatient Parenteral Antimicrobial Therapy and Judicious Use of Pediatric Emergency Resources. Pediatr Emerg Care. 2017.Google Scholar
  17. 17.
    Akar A, Singh N, Hyun DY. Appropriateness and safety of outpatient parenteral antimicrobial therapy in children: opportunities for pediatric antimicrobial stewardship. Clin Pediatr (Phila). 2014;53(10):1000–3.CrossRefGoogle Scholar
  18. 18.
    Mace AO, McLeod C, Yeoh DK, Vine J, Chen YP, Martin AC, et al. Dedicated paediatric outpatient parenteral antimicrobial therapy medical support: a pre-post observational study. Arch Dis Child. 2018;103(2):165–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Patel SV. The evolution of outpatient parenteral antibiotic therapy. Arch Dis Child. 2016;101(10):873–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Patel SV, Vergnano S. The impact of paediatric antimicrobial stewardship programmes on patient outcomes. Curr Opin Infect Dis. 2018;31(3):216–23.PubMedGoogle Scholar
  21. 21.
    •• McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis. 2016;16(8):e139–52 Evidence based guidelines on the treatment of infections in children. CrossRefPubMedGoogle Scholar
  22. 22.
    Goldman JL, Richardson T, Newland JG, Lee B, Gerber JS, Hall M, et al. Outpatient parenteral antimicrobial therapy in pediatric Medicaid enrollees. J Pediatric Infect Dis Soc. 2017;6(1):65–71.PubMedGoogle Scholar
  23. 23.
    Newland JG, Gerber JS, Kronman MP, Meredith G, Lee BR, Thurm C, et al. Sharing antimicrobial reports for pediatric stewardship (SHARPS): a quality improvement collaborative. J Pediatric Infect Dis Soc. 2018;7(2):124–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Durojaiye OC, Kritsotakis EI, Johnston P, Kenny T, Ntziora F, Cartwright K. Developing a risk prediction model for 30-day unplanned hospitalization in patients receiving outpatient parenteral antimicrobial therapy. Clin Microbiol Infect. 2018.Google Scholar
  25. 25.
    Allison GM, Muldoon EG, Kent DM, Paulus JK, Ruthazer R, Ren A, et al. Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy. Clin Infect Dis. 2014;58(6):812–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Ibrahim LF, Hopper SM, Connell TG, Daley AJ, Bryant PA, Babl FE. Evaluating an admission avoidance pathway for children in the emergency department: outpatient intravenous antibiotics for moderate/severe cellulitis. Emerg Med J. 2017;34(12):780–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Scanlan BT, Ibrahim LF, Hopper SM, Babl FE, Davidson A, Bryant PA. Selected children with complicated acute urinary tract infection may be treated with outpatient parenteral antibiotic therapy at home directly from the emergency department. Pediatr Infect Dis J. 2019;38(2):e20–e5.CrossRefPubMedGoogle Scholar
  28. 28.
    Alkhateeb A, Morin F, Aziz H, Manogaran M, Guertin W, Duval M. Outpatient management of pediatric acute mastoiditis. Int J Pediatr Otorhinolaryngol. 2017;102:98–102.CrossRefPubMedGoogle Scholar
  29. 29.
    Orme LM, Babl FE, Barnes C, Barnett P, Donath S, Ashley DM. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial. Pediatr Blood Cancer. 2014;61(8):1427–33.CrossRefPubMedGoogle Scholar
  30. 30.
    •• Bryant PA, Katz NT. Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review. Lancet Infect Dis. 2018;18(2):e45–54 An excellent systematic review of the evidence for managing children within pOPAT services. CrossRefPubMedGoogle Scholar
  31. 31.
    Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med. 2010;182(9):1137–43.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Termoz A, Touzet S, Bourdy S, Decullier E, Bouveret L, Colin C, et al. Effectiveness of home treatment for patients with cystic fibrosis: the intravenous administration of antibiotics to treat respiratory infections. Pediatr Pulmonol. 2008;43(9):908–15.CrossRefPubMedGoogle Scholar
  33. 33.
    Proesmans M, Heyns L, Moons P, Havermans T, De Boeck K. Real life evaluation of intravenous antibiotic treatment in a paediatric cystic fibrosis centre: outcome of home therapy is not inferior. Respir Med. 2009;103(2):244–50.CrossRefPubMedGoogle Scholar
  34. 34.
    • Jenkins A, Hills T, Santillo M, Gilchrist M. Drug Stability Working Group of the BUKOI. Extended stability of antimicrobial agents in administration devices. J Antimicrob Chemother. 2017;72(4):1217–20 A review of the literature on the stability of antimicrobials within elastomeric devices. Demonstrates a paucity of high-quality stability data. PubMedGoogle Scholar
  35. 35.
    • Allwood MC, Stonkute D, Wallace A, Wilkinson A-S, Hills T, Jamieson C. Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements. 2018:ejhpharm-2018-001515. Data on flucloxacillin stability over 24-hours within 2 different elastomeric devices. Demonstrates the importance of citrate-buffering to ensure drug stability over a 24 hour period. Google Scholar
  36. 36.
    Jamieson C, Allwood MC, Stonkute D, Wallace A, Wilkinson A-S, Hills T. Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting. 2019:ejhpharm-2018-001699.Google Scholar
  37. 37.
    Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus JC, et al. How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis? Antimicrob Agents Chemother. 2014;58(5):2849–55.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Van Winkle P, Whiffen T, Liu IL. Experience using peripherally inserted central venous catheters for outpatient parenteral antibiotic therapy in children at a community hospital. Pediatr Infect Dis J. 2008;27(12):1069–72.CrossRefPubMedGoogle Scholar
  39. 39.
    Hussain S, Gomez MM, Wludyka P, Chiu T, Rathore MH. Survival times and complications of catheters used for outpatient parenteral antibiotic therapy in children. Clin Pediatr (Phila). 2007;46(3):247–51.CrossRefGoogle Scholar
  40. 40.
    Kovacich A, Tamma PD, Advani S, Popoola VO, Colantuoni E, Gosey L, et al. Peripherally inserted central venous catheter complications in children receiving outpatient parenteral antibiotic therapy (OPAT). Infect Control Hosp Epidemiol. 2016;37(4):420–4.CrossRefPubMedGoogle Scholar
  41. 41.
    Fernandes P, Milliren C, Mahoney-West HM, Schwartz L, Lachenauer CS, Nakamura MM. Safety of outpatient parenteral antimicrobial therapy in children. Pediatr Infect Dis J. 2018;37(2):157–63.CrossRefPubMedGoogle Scholar
  42. 42.
    Hodgson KA, Huynh J, Ibrahim LF, Sacks B, Golshevsky D, Layley M, et al. The use, appropriateness and outcomes of outpatient parenteral antimicrobial therapy. Arch Dis Child. 2016;101(10):886–93.CrossRefPubMedGoogle Scholar
  43. 43.
    Yusef D, Gonzalez BE, Foster CB, Goldfarb J, Saracusa C, Worley S, et al. Piperacillin-Tazobactam-induced adverse drug events in pediatric patients on outpatient parenteral antimicrobial therapy. Pediatr Infect Dis J. 2017;36(1):50–2.CrossRefPubMedGoogle Scholar
  44. 44.
    Chrysochoou EA, Hatziagorou E, Kirvassilis F, Tsanakas J. Home intravenous antibiotic therapy in children with cystic fibrosis: clinical outcome, quality of life and economic benefit. Hippokratia. 2016;20(4):279–83.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Gauthier M, Chevalier I, Sterescu A, Bergeron S, Brunet S, Taddeo D. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center. Pediatrics. 2004;114(4):e469–76.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Paediatric Infectious Diseases & Immunology, Southampton Children’s HospitalUniversity Hospital Southampton NHS Foundation TrustSouthamptonUK
  2. 2.NIHR Biomedical Research CentreUniversity Hospital Southampton NHS Foundation TrustSouthamptonUK
  3. 3.NIHR Wellcome Trust Clinical Research FacilityUniversity Hospital Southampton NHS Foundation TrustSouthamptonUK

Personalised recommendations